205 related articles for article (PubMed ID: 11295599)
1. Proapoptotic anti-inflammatory drugs.
Myers C; Koki A; Pamukcu R; Wechter W; Padley RJ
Urology; 2001 Apr; 57(4 Suppl 1):73-6. PubMed ID: 11295599
[TBL] [Abstract][Full Text] [Related]
2. Dual acting anti-inflammatory drugs: a reappraisal.
Bertolini A; Ottani A; Sandrini M
Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348
[TBL] [Abstract][Full Text] [Related]
3. Celecoxib with chemotherapy in colorectal cancer.
Blanke CD
Oncology (Williston Park); 2002 Apr; 16(4 Suppl 3):17-21. PubMed ID: 12014863
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of cyclooxygenase-2-specific inhibitors.
Cannon GW; Breedveld FC
Am J Med; 2001 Feb; 110 Suppl 3A():6S-12S. PubMed ID: 11173044
[TBL] [Abstract][Full Text] [Related]
5. Cyclooxygenase inhibition in cancer--a blind alley or a new therapeutic reality?
Chau I; Cunningham D
N Engl J Med; 2002 Apr; 346(14):1085-7. PubMed ID: 11932478
[No Abstract] [Full Text] [Related]
6. COX-2-Selective NSAIDs: new and improved?
Lichtenstein DR; Wolfe MM
JAMA; 2000 Sep; 284(10):1297-9. PubMed ID: 10980759
[No Abstract] [Full Text] [Related]
7. Chemoprevention strategies using NSAIDs and COX-2 inhibitors.
Keller JJ; Giardiello FM
Cancer Biol Ther; 2003; 2(4 Suppl 1):S140-9. PubMed ID: 14508092
[TBL] [Abstract][Full Text] [Related]
8. Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention.
Kismet K; Akay MT; Abbasoglu O; Ercan A
Cancer Detect Prev; 2004; 28(2):127-42. PubMed ID: 15068837
[TBL] [Abstract][Full Text] [Related]
9. NSAIDs and chemoprevention.
Rao CV; Reddy BS
Curr Cancer Drug Targets; 2004 Feb; 4(1):29-42. PubMed ID: 14965265
[TBL] [Abstract][Full Text] [Related]
10. Approach to angiogenesis inhibition based on cyclooxygenase-2.
Masferrer J
Cancer J; 2001; 7 Suppl 3():S144-50. PubMed ID: 11779086
[TBL] [Abstract][Full Text] [Related]
11. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
Jacoby RF; Seibert K; Cole CE; Kelloff G; Lubet RA
Cancer Res; 2000 Sep; 60(18):5040-4. PubMed ID: 11016626
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway.
Yasumaru M; Tsuji S; Tsujii M; Irie T; Komori M; Kimura A; Nishida T; Kakiuchi Y; Kawai N; Murata H; Horimoto M; Sasaki Y; Hayashi N; Kawano S; Hori M
Cancer Res; 2003 Oct; 63(20):6726-34. PubMed ID: 14583467
[TBL] [Abstract][Full Text] [Related]
13. COX-2 inhibition and colorectal cancer.
Koehne CH; Dubois RN
Semin Oncol; 2004 Apr; 31(2 Suppl 7):12-21. PubMed ID: 15252926
[TBL] [Abstract][Full Text] [Related]
14. The new NSAIDs: cox-2 inhibitors.
Capriotti T
Medsurg Nurs; 2000 Dec; 9(6):313-7. PubMed ID: 11904867
[No Abstract] [Full Text] [Related]
15. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
Geis GS
Scand J Rheumatol Suppl; 1999; 109():31-7. PubMed ID: 10422544
[TBL] [Abstract][Full Text] [Related]
16. Coming: a review of second-generation nonsteroidal anti-inflammatory drugs.
Housholder GT; Chan JT
J Gt Houst Dent Soc; 1997 Mar; 68(8):13-6. PubMed ID: 9594801
[No Abstract] [Full Text] [Related]
17. 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells.
Shureiqi I; Chen D; Lotan R; Yang P; Newman RA; Fischer SM; Lippman SM
Cancer Res; 2000 Dec; 60(24):6846-50. PubMed ID: 11156377
[TBL] [Abstract][Full Text] [Related]
18. Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells.
He Q; Luo X; Huang Y; Sheikh MS
Oncogene; 2002 Sep; 21(39):6032-40. PubMed ID: 12203115
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of nonsteroidal anti-inflammatory drug-induced gastrointestinal injury and repair: a window of opportunity for cyclooxygenase-inhibiting nitric oxide donors.
Perini R; Fiorucci S; Wallace JL
Can J Gastroenterol; 2004 Apr; 18(4):229-36. PubMed ID: 15054499
[TBL] [Abstract][Full Text] [Related]
20. COX-2-specific inhibition: implications for clinical practice.
Pascucci RA
J Am Osteopath Assoc; 1999 Nov; 99(11 Suppl):S18-22. PubMed ID: 10643177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
